Yu Cuiling, Ehrhardt Götz R A, Alder Matthew N, Cooper Max D, Xu Anlong
Department of Biochemistry, State Key Laboratory of Biocontrol, College of Life Sciences, Sun Yat-sen University, Guangzhou, PR China.
Eur J Immunol. 2009 Feb;39(2):571-9. doi: 10.1002/eji.200838846.
A TCR-like molecule (TCRL) with two canonical ITIM has been identified in the sea lamprey. We show here that TCRL is preferentially expressed by lymphocytes bearing variable lymphocyte receptors. To examine the potential of the TCRL inhibitory motifs, chimeric proteins comprising the FcgammaRIIb extracellular and transmembrane domains and the TCRL intracellular domain were expressed in a mouse B-cell line. BCR co-ligation with the WT version of the FcgammaRIIb/TCRL chimeric protein resulted in its tyrosine phosphorylation and the inhibition of BCR-induced calcium mobilization, whole-cell protein tyrosine phosphorylation and Erk/Akt/JNK activation. Tyrosine to phenylalanine mutations in either or both ITIM compromised the inhibitory capacity of this receptor chimera. Analysis of receptor-associated proteins indicated that the inhibition is mediated by recruitment of the protein tyrosine kinases, SHP1 and SHP2. These findings demonstrate the inhibitory potential of TCRL and its expression by clonally diverse lymphocytes bearing the variable lymphocyte receptors, thereby implying an immunomodulatory role for this ancestral TCR relative in a jawless vertebrate.
在海七鳃鳗中已鉴定出一种具有两个典型免疫受体酪氨酸抑制基序(ITIM)的类T细胞受体分子(TCRL)。我们在此表明,TCRL优先由携带可变淋巴细胞受体的淋巴细胞表达。为了研究TCRL抑制基序的潜力,在小鼠B细胞系中表达了包含FcγRIIb细胞外和跨膜结构域以及TCRL细胞内结构域的嵌合蛋白。BCR与FcγRIIb/TCRL嵌合蛋白的野生型版本共连接导致其酪氨酸磷酸化,并抑制BCR诱导的钙动员、全细胞蛋白酪氨酸磷酸化以及Erk/Akt/JNK激活。任一或两个ITIM中的酪氨酸突变为苯丙氨酸都会损害该受体嵌合体的抑制能力。对受体相关蛋白的分析表明,这种抑制作用是由蛋白酪氨酸激酶SHP1和SHP2的募集介导的。这些发现证明了TCRL的抑制潜力及其在携带可变淋巴细胞受体的克隆多样化淋巴细胞中的表达,从而暗示了这种原始TCR在无颌脊椎动物中的免疫调节作用。